Items where Author is "Turkoglu, R."

(2025) First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis. Neurotherapeutics. p. 12. ISSN 1933-7213

(2025) Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study. Journal of neurology, neurosurgery, and psychiatry. pp. 361-369. ISSN 1468-330X (Electronic) 0022-3050 (Linking)

(2025) Progression independent of relapse activity and relapse-associated worsening in seronegative NMOSD: an international cohort study. Journal of Neurology. p. 339. ISSN 1432-1459 (Electronic) 0340-5354 (Print) 0340-5354 (Linking)

(2025) Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis. JAMA neurology. ISSN 2168-6157 (Electronic) 2168-6149 (Print) 2168-6149 (Linking)

(2024) Disease Activity in Pregnant and Postpartum Women with Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies. Neurology: Neuroimmunology and NeuroInflammation. ISSN 23327812 (ISSN)

(2024) How patients with neuromyelitis optica spectrum disorder accumulate disability. Multiple Sclerosis Journal. pp. 1158-1160. ISSN 1352-4585

(2024) Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study. Journal of Neurology Neurosurgery and Psychiatry. p. 9. ISSN 0022-3050

(2024) Prevalence of Progression Independent of Relapse Activity and Relapse-Associated Worsening in Patients With AQP4-IgG-Positive NMOSD. Neurology. e209940. ISSN 1526-632X (Electronic) 0028-3878 (Linking)

(2024) A standardised definition of progression independent of relapse activity in multiple sclerosis. Multiple Sclerosis Journal. pp. 442-445. ISSN 1352-4585

(2023) Comparative effectiveness in multiple sclerosis: A methodological comparison. Multiple Sclerosis Journal. pp. 326-332. ISSN 1352-4585

(2023) Disability accrual in primary and secondary progressive multiple sclerosis. Journal of Neurology Neurosurgery and Psychiatry. pp. 707-717. ISSN 0022-3050

(2023) Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal. pp. 875-883. ISSN 1352-4585

(2023) Effect of high-efficacy therapy on the course of disability in paediatric-onset multiple sclerosis. Multiple Sclerosis Journal. pp. 103-105. ISSN 1352-4585

(2023) External validation of a clinical prediction model in multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England). pp. 261-269. ISSN 1477-0970 (Electronic) 1352-4585 (Linking)

(2023) Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis. European Journal of Neurology. pp. 1014-1024. ISSN 1351-5101

(2022) Confirmed disability progression as a marker of permanent disability in multiple sclerosis. European Journal of Neurology. pp. 2321-2334. ISSN 13515101 (ISSN)

(2022) Confirmed disability progression as a marker of permanent disability in multiple sclerosis. EUROPEAN JOURNAL OF NEUROLOGY. pp. 2321-2334. ISSN 1351-5101 1468-1331 J9 - EUR J NEUROL

(2022) Description of Multiple Sclerosis cohorts from the Middle East between 2009 and 2019. Multiple Sclerosis Journal. pp. 17-18. ISSN 1352-4585

(2022) Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis. NEUROLOGY. ISSN 0028-3878

(2022) Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis. Bmc Medical Research Methodology. p. 14.

(2022) Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis. BMC MEDICAL RESEARCH METHODOLOGY. ISSN 1471-2288 J9 - BMC MED RES METHODOL

(2022) Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS. Mult Scler. p. 13524585221084577. ISSN 1352-4585

(2022) The risk of secondary progressive multiple sclerosis is geographically determined but modifiable. Multiple Sclerosis Journal. pp. 967-970. ISSN 1352-4585

(2021) Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. Multiple Sclerosis Journal. pp. 755-766. ISSN 1352-4585

(2021) Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009-2018. CNS Drugs. ISSN 1172-7047

(2021) The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies. Mult Scler Relat Disord. p. 103012. ISSN 2211-0348

(2019) Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. J Neurol Neurosurg Psychiatry. pp. 458-468. ISSN 1468-330X (Electronic) 0022-3050 (Linking)

(2018) Disability outcomes in patients with early cerebellar symptoms in multiple sclerosis. Multiple Sclerosis Journal. pp. 135-137. ISSN 1352-4585